FDA clears UltraSPECT's PET application

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

The FDA has cleared UltraSPECT’s Xpress.PET product, a whole-body PET application, which will be offered for sale immediately in the U.S. market.

Xpress.PET is based on UltraSPECT's Wide-Beam Reconstruction (WBR) technology. The Auburndale, Mass.-based company said its WBR products for gamma cameras have been utilized for cardiac and oncology applications in the U.S. and Europe since 2005. The new Xpress.PET expands the WBR product family with additional modality applications.